Founded in 1974 by Dr. Barry Sherman, we’re a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines (both generic and innovative pharmaceuticals) for patients around the world.
From its humble origins of only two employees, we’ve grown to employ more than 11,000 people worldwide in manufacturing, R&D and commercial operations.
Through vertical integration, the Apotex Group of Companies is comprised of Apotex Generics, Apotex Active Pharmaceutical Ingredients, Apobiologix and ApoPharma (innovative products).
We export to more than 115 countries and territories and operate in more than 45 countries, including a significant presence in the US, Mexico, and India where we continue to invest.
Our footprint includes an expanding network of Affiliates and Distributors, as well as joint ventures and strategic alliances.
Globally, we produce approximately 25 billion doses per year, which, in turn, are used to fill approximately 90 million prescriptions in Canada alone or one in five prescriptions.
In the past five years alone, we have helped to bring more than 20 prescription drugs to market before patent expiry, and in doing so, saved public and private payers more than $4 billion. In total, we have saved Canadians almost $19 billion by bringing products to market early.
We are the single largest investor in research and development of any pharmaceutical company in Canada – brand or generic.
We have the largest labs in the Canadian pharmaceutical industry and more than 1100 active R&D projects representing more than 500 molecules in 50 countries.
In the past 10 years, we have invested $1 billion in research and development, with an additional $2 billion planned for the next 10 years.
Sherman murder probe obtains seven more search warrants
Det.-Sgt. Susan Gomes is the lead investigator now examining the suspicious deaths of billionaires Barry and Honey Sherman.
Billionaire Barry Sherman filed a lawsuit to quash an investigation into a Liberal Party fundraiser he hosted that may have breached lobbying rules
In 2013, Apotex began selling a biosimilar version of Amgen's Neulasta in Europe, a blockbuster drug used by cancer patients in chemotherapy as a way to boost white blood count. Apotex's version is known as Grastofil (filgrastim) and is licensed for sale in Europe by Stada Arzneimittel. In February 2015, the FDA accepted Apotex's application of its filing of Grastofil in the United States
A critical review of Miriam Shuchman's 2005 book about Dr. Nancy Olivieri versus Apotex, summarizes how "Nancy Olivieri is famous for raising doubts about an experimental drug with which she was treating thalassemia patients.
Her principled stand and the resulting scandal led universities to offer researchers some protection against illegitimate drug company pressure.
Medical journals changed their publication rules. Research hospitals changed their policies. She became an international icon. Apotex, the drug company which tried to silence her, has attracted international opprobrium.
The company threatened to sue Olivieri if she publicly revealed her fears about the inadequacy of their drug, deferiprone. She sued them for libeling her; they sued her ($20 million) for libeling their drug."
Posted: Jan 27, 2018 11:54 AM ET
Fri., Jan. 26, 2018
Wed., Jan. 31, 2018
Tues., Jan. 2, 2018
Jul 14, 2018, 01:00 ET